Insights

iStock1752319741080x675

Telepharma Disconnect: Federal Circuit Reverses PTAB on Obviousness, PTAB Litigation Blog

Visit the PTAB Litigation Blog.

On May 28, the Federal Circuit reversed a PTAB inter partes review (“IPR”) decision that held Baxter Corporation Englewood’s (“Baxter’s”) claims were not invalid under 35 U.S.C. § 103(a) obviousness based on three prior art references: Alexander, Liff, and Morrison. The appeal involved telepharmacy technology for providing drug information to a pharmacist for approval while other non-pharmacists prepare the order. At issue on appeal were two limitations of the 8,554,579 (“579 patent”), referred to as the “verification limitation” and the “highlighting limitation.” The verification limitation relates to steps that must be verified as completed before the pharmacist can continue and the highlighting limitation relates to interactive screens that include prompts which can be highlighted for additional information on the relevant step. The ‘579 patent was one of three patents asserted by Baxter against the medical technology company Becton, Dickinson, and Company (“Becton”) in a parallel litigation in the Southern District of California. The opinion, written by Judge Dyk, concluded that “the Board’s determination that the verification and highlighting limitations are not obvious is not supported by substantial evidence.”

Read the full article at ptablitigationblog.com.

Jones Day publications should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request reprint permission for any of our publications, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. The mailing of this publication is not intended to create, and receipt of it does not constitute, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.

 
We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.